The Recap: July 2024

The Recap: July 2024

Since our founding in 2017, Velocity’s trajectory has been one of growth.

With 90 sites globally and expanding, our footprint and capacity have grown. More importantly, we’ve been focused on leveraging that growth to build new technologies and processes that are empowering this industry to evolve in essential ways.

We’re building our proprietary VISION technology to identify and engage patients more effectively. VISION just contributed to its 2,000th patient randomization and is now delivering study stipend payments to patients through the VISION Engage app. We have some exciting VISION announcements coming from our team in Hyderabad very soon. Internally, our CARE Councils and investigator collaboration programs are sparking earlier engagement with Sponsors seeking physician feedback to guide protocol development.

We started Velocity with a goal that is rapidly coming to fruition — scale is empowering us to facilitate more predictable, more efficient clinical trials.

We’re excited to bring these economies of scale to oncology.

Our recently announced partnership with Luminis Health marks our entry into oncology clinical trials in the U.S. Several of our sites in Poland have also supported oncology trials. With experienced sites and investigators on two continents, our entry into oncology is an exciting move, both for Velocity and anyone with a promising oncology candidate.

Thank you for joining us on this journey. Here’s to advancing this industry together.

Craig Koch

Executive Vice President, Business Development

[email protected]


Velocity Partners With Luminis Health, Moves Into Oncology in the U.S.

Velocity and Luminis Health, a nonprofit health system providing care for 1.8 million people, have partnered to conduct clinical research within the health group’s organization, connecting more patients with community-based research programs.

Read more >


VISION Reaches 2,000+ Patients Randomized

Just one year ago, VISION technology empowered its first patient to self-screen and self-schedule a visit for a clinical trial at Velocity. Today, VISION has contributed to more than 2,000 randomizations.

Read more >


Spotlight: Meet Velocity's Principal Investigators in the U.K.

Principal investigators at Velocity's U.K. sites have collectively supported more than 100 clinical trials. Several of our U.K. sites were also recently renovated or expanded, and now have access to 600,000 potential participants through internal and partner databases.?

View the PDF >


Featured Video: Former Surgeon General Jerome Adams, MD, MPH

In June, we welcomed former Surgeon General Jerome Adams, MD, MPH , to an internal presentation about the importance and direction of diversity in clinical trials, followed by a Q&A hosted by Paul Evans . This clip is from the first of a three-part series that centered on inclusivity, diversity, and the patient experience.

You’re starting from a trust deficit … People need to know that you care before they care what you know.

View the LinkedIn post >


Subscribe to The Recap


Love the update and news Craig, such exciting times. Wishing you only more success.

回复
Elaine Bartlett

AIRGAS AP Payments Processing,

4 个月

Awesome update Craig!

回复

要查看或添加评论,请登录

社区洞察

其他会员也浏览了